SEC filings and other documents

Multiple first-in-class radiopharmaceuticals advance in parallel, with key data readouts expected soon.

Strong clinical progress and milestone-driven cash outflows, with funding actions underway.

RAD101 PET imaging shows 90% success in phase II-B for brain metastases, outperforming MRI.

RAD101 nears phase II completion with strong results; key pipeline readouts expected this year.

Clinical progress and $35M raise extend funding runway, with key trials advancing in 2026.

First-in-class radiopharmaceuticals advance toward pivotal data and partnerships by 2026.

IND approval, clinical progress, and $35M placement extend funding runway into 2027.

Interim Phase IIb data show RAD-101 PET imaging improves detection of active brain metastases.

RAD101 targets a $500M+ US market as the only PET agent for brain metastases, with key trials ongoing.

Differentiated radiopharmaceutical pipeline advances with strong partnerships and 2026 milestones.

Advancing six clinical programs with strong funding, promising data, and major milestones ahead.

RAD-101 shows strong promise as a novel imaging agent for brain metastases, addressing a major unmet need.

B7-H3-targeted BetaBart shows strong preclinical promise and is advancing to clinical trials.

Robust cash reserves and clinical progress position the company for key milestones in 2025.

Lantheus' strategic investment and strong clinical progress extend Radiopharm's funding runway.

Broad, innovative radiopharmaceutical pipeline advances toward key clinical milestones through 2026.

First-in-class radiopharmaceuticals advance in oncology, with key data readouts expected mid-2024.

$8M Lantheus placement extends cash runway as Radiopharm advances clinical pipeline.

$70M capital raised and strong cash position fuel Radiopharm's clinical and US expansion.

A$70 million capital raise and clinical progress position the company for growth through 2026.

$70M raised, clinical milestones achieved, and cash runway extended to three quarters.